SecBot SecBot

SNDX drug pipeline

$9.13
−3.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±7.4%
1-day, median of 2 events
IV rank
No data
No current options data
Rated drugs
4
2 bullish · 2 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved
Time to marketAlready approved and commercially launched (FDA approved August 2024)

Niktimvo axatilimab-csfr Updated Jul 14

What to watch

Niktimvo's commercial trajectory is the primary value driver for SNDX on this drug. Watch Q2/Q3 2026 net revenue prints for signs of continued ramp ($151.6M FY2025 annualizing to ~$220M in Q1 2026). The Phase 2 IPF readout in Q4 2026 is an important optionality catalyst that could open a much larger market, but comes with clinical risk. The $250M convertible note issued June 2026 introduces modest dilution overhang (~8-10% of shares outstanding).

Bull case
  • First-in-class mechanism targeting CSF-1R/macrophage axis, differentiated from Jakafi (JAK inhibitor), Rezurock (ROCK2 inhibitor), and Imbruvica (BTK inhibitor) in the cGVHD market.
  • Rapid commercial uptake: net revenue grew from $13.6M (Q1 2025) to $56M (Q4 2025), with Q1 2026 net revenue of $55M signaling continued strong launch trajectory.
  • Phase 2 IPF trial (MAXPIRe) topline data in Q4 2026 opens a much larger addressable market, IPF is a multi-billion-dollar indication with high unmet need.
Bear case
  • cGVHD is a niche indication, even as the third entrant behind Jakafi and Rezurock, Niktimvo faces competition for a relatively small patient population and may struggle to differentiate on efficacy (ORR appears comparable per cross-trial meta-analyses).
  • Niktimvo's economics for Syndax are diluted: Incyte records all product revenue and Syndax gets only 50% of net commercial profit after cost of sales and SG&A, plus Royalty Pharma collects a 13.8% royalty on US sales.
  • $250M convertible note issued June 2026 (2.25% coupon, due 2031) creates potential dilution of up to ~13.6M shares (~8-10% of outstanding), adding overhang.
▲ bullish
Impact
PhaseApproved
Time to marketAlready FDA-approved and commercializing (first approval Nov 2024, second Oct 2025)

Revuforj revumenib Updated Jul 14

What to watch

Watch quarterly Revuforj revenue growth and market share vs. Kura's Komzifti (ziftomenib), which entered the same NPM1-mutated AML space in Nov 2025. Also monitor the Phase 1/2 SAVE combination trial data and the planned myelofibrosis trial (4Q26 start), any early efficacy signal would open a much larger market. Near-term stock direction hinges on commercial execution rather than binary trial reads.

Bull case
  • Revuforj is a first-in-class menin inhibitor with two FDA-approved labels covering both KMT2A-rearranged and NPM1-mutated acute leukemias, the only drug with both indications (FDA press release and Syndax press release confirm).
  • Commercial momentum is strong: Revuforj net revenue grew 144% YoY to $48.9M in Q1 2026 and generated ~$125M in FY2025; combined platform with Niktimvo annualizing at ~$200M (Syndax Q1 2026 press release).
  • Analyst consensus is Strong Buy (19 Buy incl. 8 Strong Buy, 1 Hold, 0 Sell) with a mean price target of $39, implying ~76% upside from $22.89.
Bear case
  • Direct competition from Kura Oncology's Komzifti (ziftomenib), which was FDA-approved for NPM1-mutated AML in Nov 2025 with a potential safety advantage (FDA approval, also Medpage Today report, FiercePharma and trial.medpath.com articles).
  • Both FDA approval events (Nov 2024 and Oct 2025) saw the stock decline on the news, -5.7% one-day and -5% five-day for the first, -7.8% one-day and -10% five-day for the second, suggesting sell-the-news dynamics.
  • CEO Michael Metzger sold ~$785K of stock via a 10b5-1 plan on July 8, 2026 at ~$24.24, and the CMO sold ~$567K in June 2026.
● neutral
Impact
PhasePreclinical (IND-enabling)
Time to marketUnknown — preclinical; IND filing targeted by end of 2026, Phase 1 in 2027. Commercialization would be years away if clinical trials succeed.

SNDX-4321 Updated Jul 14

What to watch

SNDX-4321 is too early-stage to drive meaningful stock movement. Investors should focus on Syndax's nearer-term catalysts: upcoming Phase 2 data for axatilimab in IPF (4Q26) and cGVHD (4Q26), and the commercial ramp of approved products Revuforj and Niktimvo (~$200M combined annualizing as of 1Q26).

Bull case
  • Mutant-selective allosteric EGFR inhibitors represent a potentially differentiated approach vs. existing EGFR TKIs; if successful, SNDX-4321 could address NSCLC patients with high unmet need.
  • Syndax has experience bringing cancer drugs to market (Revuforj approved Dec 2024, Niktimvo approved Aug 2024), providing a commercial infrastructure that could support future launches.
  • The molecule was disclosed at a dedicated R&D event, suggesting management sees meaningful potential, and the exclusive worldwide license structure aligns incentives.
Bear case
  • SNDX-4321 is preclinical, no human efficacy or safety data exist. The vast majority of preclinical oncology candidates fail before or during Phase 1.
  • The EGFR inhibitor space is intensely competitive, with approved drugs from AstraZeneca (osimertinib/Tagrisso), Johnson & Johnson, and others already established as standard of care.
  • IND filing >12 months away means no near-term catalyst; this is a long-duration, high-risk pipeline option that provides optionality at best.
● neutral
Impact
PhasePreclinical
Time to marketUnknown — many years out. IND is targeted for 2027 and Phase 1 follows, so any approval (if the drug ever gets there) is realistically years beyond that.

SNDX-62122 Updated Aug 17

What to watch

Treat SNDX-62122 as a long-dated, option-like pipeline line item, not a near-term trade catalyst, there is no dated binary for this molecule itself within ~12 months (IND is a 2027 target). Investors positioned in SNDX should instead focus on the Q4 2026 axatilimab IPF/cGVHD data and the Q4 2026 start of the revumenib myelofibrosis trial, which is the earliest real-world read on the menin-in-MF hypothesis this drug depends on.

Bull case
  • Wholly owned and internally developed: SNDX-62122 is the first candidate from Syndax's next-generation menin inhibitor library, giving the company a follow-on asset it fully controls (finance.yahoo.com; ir.syndax.com).
  • Program is designed to be de-risked: development will be informed by the revumenib Phase 1/2 proof-of-principle trial in myelofibrosis, expected to initiate Q4 2026 with initial data 2H 2027, so Syndax gets an early clinical read on the menin-in-myelofibrosis thesis before SNDX-62122's own IND (ir.syndax.com; syndax.com/pipeline).
  • Parent company is commercial-stage with two FDA-approved drugs (Revuforj, Niktimvo) annualizing at roughly $200M combined as of 1Q26, and analysts are bullish: 18 of 19 ratings are Buy/Strong Buy with a mean price target of ~$37.9 vs. a ~$19.84 stock price.
Bear case
  • Pure preclinical risk: no clinical data exist, the IND is not targeted until 2027, and typical early-stage oncology attrition means most candidates never reach approval (adisinsight.springer.com; synapse.patsnap.com).
  • The myelofibrosis mechanism is unproven, even revumenib, the company's own menin inhibitor, is only approved in NPM1-mutated AML, so SNDX-62122 depends on a thesis that has yet to show clinical validation.
  • SNDX-62122 is a small part of the SNDX story: near-term stock drivers are axatilimab IPF/cGVHD data (expected 4Q26) and commercial execution, not this preclinical asset, so standalone news around it is unlikely to move the stock much.

Past FDA events & how the stock moved

2 events
DateDrugEvent1 day5 days
Oct 24, 2025RevuforjApproval−10.7%−6.7%
Nov 15, 2024RevuforjApproval−4.0%−4.2%

Clinical trials

2 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
NiktimvoMAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)Phase 2Completed145Aug 27, 2026
RevuforjEvaluation of Revumenib in Participants With Colorectal Cancer and Other Solid TumorsPhase 2Terminated · results41Jun 30, 2025